Background: Immune thrombocytopenia (ITP) is an immune-mediated hematologic disorder in which increased platelet destruction and decreased platelet production lead to thrombocytopenia and, thus, mucocutaneous bleeding. The interleukin-1 (IL-1) family is involved in many human diseases by regulating innate immunity and inflammation. As a new IL-1 family member found in 2005, IL-33 and its receptor play important roles in inflammation, cancer, allergy and autoimmune diseases and are potential therapeutic targets. The aim of this work was to evaluate IL-33 among active ITP patients and remission in relation to control.
INTRODUCTION
mmune thrombocytopenia (ITP) is an immune-mediated hematologic disorder in which increased platelet destruction and decreased platelet production lead to thrombocytopenia and, thus, mucocutaneous bleeding. The pathophysiology of ITP has been extensively investigated. It is generally accepted that a complex multifactorial immune dysregulation, loss of immune tolerance, and generation of platelet autoantibodies account for the primary mechanism. Nevertheless, the underlying pathogenic events leading to the breakdown of immune tolerance in ITP remain elusive (1) .In children, the disease sometimes follows a viral infection. In adults, it is more often a long-term (chronic) disease and can occur after a viral infection, with use of certain drugs, during pregnancy, or as part of an immune disorder. ITP affects women more often than men. It is more common in children than adults. In children, the disease affects boys and girls equally. ITP symptoms can include any of the following: Bleeding into the skin, often around the shins, causing a skin rash that looks like pinpoint red spots (petechial rash), Easy bruising and Nosebleed or bleeding in the mouth ( 
2)
The interleukin-1 (IL-1) family is involved in many human diseases by regulating innate immunity and inflammation
(3).
As a new IL-1 family member found in 2005, IL-33 and its receptor play important roles in inflammation, cancer, allergy and autoimmune diseases and are potential therapeutic targets ( 
4)
The value of IL-33 observed in patient with ITP correlated with disease activity, considering the role of IL-33 in regulating T cell immunity , studies on IL-33 in ITP would further improve our understanding of the pathogenesis of ITP
(5).
The aim of this work was to evaluate IL-33 among active ITP patients and remission in relation to control.
SUBJECTS AND METHODS 1-Subjects:
This is a case control study This study was conducted in the Outpatient Clinic of Hematology Unit of Pediatric Department and Clinical Pathology Department at Zagazig university hospitals during the period from October 2017 to April 2018. Formal consent was obtained from all individual and the study protocol was approved by the Zagazig medical research ethical committee on Twenty two ITP Patients during their regular follow-up visits and Twenty two age and sexmatched healthy children as a control group.
Forty four subjects were included in this study; they were classified into two groups as follow: A) Control group : It included 22 apparently healthy subjects. They were 16 males and 9 females. Their ages ranged from 3-9 years. They matched well with patients as regard age and sex . it evaluates the linear association between 2 quantitative variables ( one is the independent var.X, and the other is the dependent var., Y). value of "r" ranges from -1 to 1 0= no linear correlation 1= perfect positive correlation -1 = perfect negative correlation Positive= increase in the independent variable leads to increase in the dependent variable Negative = increase in the independent variable leads to decrease in the dependent variable 2. Level of significance: (P-value).
 P value of >0.05 indicates nonsignificant results.
 P value of <0.05 indicates a significant results.
4-Results:
There was no statistically significant difference between cases and control regarding sex and age. DISCUSSION This study was carried out on 44 subjects (22 cases and 22 controls).Cases are subgrouped into 2 groups (Acute, Chronic).Acute ITP group included 14 patients, they were 9 males and 5 females. Their age ranged from 2-12.Chronic ITP group included 8 patients; they were 7 males and 1 female. Their age ranged from 3-12 years. This agreed with (6) who aimed to assess the clinical role of a cytokine in patients with ITP and correlate its levels with different stages of the disease. A total of 20 patients with ITP at the onset stage, 40 patients with chronic ITP, and 30 healthy matched controls were enrolled in this study. He found that, 15.6% were males and 84.4% were females, showing a female predominance, with age range of 18-50 years with mean of 31.8 years, which was in agreement with the results of (7,8,9) All these studies were performed on patients with ITP and showed that ITP among adults affects females more than males, with no specific age predominance. On comparing our three groups, we found no statistically significant difference between them. On the contrary, (10) showed that the incidence of ITP is predominant in males in childhood. In current study clinical data in ITP group was evaluated, purpura was found in 20 patients (90.9%), followed by Ecchymosis which was found in 18 patients (81.81%). Mucous membrane bleeding was found in 16 patients (72.7%), Splenomegaly was found in one patient (4.54%), while lymphadenopathy was not found in any patients. Since platelets play a pivotal role in primary hemostasis, quantitative and/or qualitative abnormalities may present with bleeding symptoms. In patients with ITP, the most common bleeding symptoms are purpura, mucocutaneous bleeding and prolonged bleeding after minor injury. Rarely, patients may present with bleeding in vital organs or excessive bleeding after hemostatic challenge (11) This agreed with (12) found that, that the most common symptoms were skin rash (93.5%) and epistaxis (41.3%), which was significantly more among male children. The most common signs were ecchymosis (87%), purpura (76.1%), petechial rash (60.9%), bleeding in mucous membranes (58.7%) and pallor (32.6%). Splenomegaly was present in 6.5% of patients. This study showed that, mean value of platelets was significantly lower among cases than controls . Platelets count were severely decreased in ITP patients than controls due to presence of platelet autoantibodies directed against specific platelet glycoproteins, such antibodies can be detected in 40% to 80% of patients with clinical ITP. However, absence of detectable antibodies does not rule out a diagnosis of ITP, since many patients without detectable antibodies respond to traditional ITP therapies and antibodies may occur in patients with liver disease and other conditions without clinical ITP (13) This agreed with (6) who aimed to assess the clinical role of a cytokine in patients with ITP and correlate its levels with different stages of the disease. A total of 20 patients with ITP at the onset stage, 40 patients with chronic ITP, and 30 healthy matched controls were enrolled in this study. He revealed a highly statistically significant difference between the groups regarding platelets count, with lower counts in patients with acute ITP than those with chronic ITP(p˂0.001). This may be attributed to platelet destruction arises from antibodies generated during the immune response to a viral or bacterial infection in acute ITP that cross-react with platelet antigens, also other mediators of the immune response arising from infection may play an additional role in suppressing platelet production (14) Serum IL-33 was measured by using ELISA technique because it is one of the most widely used, best validated, and most sensitive immunoassays available. ELISA is also quick, easy, less expensive, and it is a very popular choice for the evaluation of various targets in clinical laboratories and biomedical research since it allows processing of even larger numbers of samples. Additional advantages of ELISA include the fact that results are highly quantitative and generally reproducible. This study showed that, mean value of IL-33 was significantly lower among cases than controls (24.68, 47.18 respectively).There was statistically decrease of IL-33 among acute ITP children than chronic ITP children (P value=.000).There was statistically decrease of IL-33 among acute ITP children than controls (P value=.000).There was no statistically significant difference between chronic ITP children and controls regarding IL-33 (P value=.769).
This agreed with (15) who aimed to measure the expression of IL-33 in active immune thrombocytopenia (ITP) compared to controlsThirty-two ITP patients measured in plasma using ELISA and compared with 27 age-and sex-matched healthy controls.IL-33 in the ITP patients with active disease were significantly lower than those of the healthy controls. Significantly lower IL-33 and higher sST2 plasma levels were found in the active ITP patients compared with the ITP patients in .However, no significant differences in the IL-33 and sST2 plasma levels were found between the ITP patients in remission and healthy controls. Interestingly, the expression of IL-33 was unchanged in the patients compared with the controls. There was no significant difference between the patients in remission and the control group. A number of studies suggest that a generalized dysregulation in immune regulatory networks may be present in ITP as in other autoimmune diseases. This study showed that, there were no statistically significant positive correlation between IL-33 and HB and RBCs. While There were statistically significant positive correlation between IL-33 ,WBCs, lymphocytes % and Platelets . (15) made correlations between the plasma IL-33 and platelet counts were analyzed in the active ITP patients. The data demonstrated no correlation between the IL-33 levels and platelet counts. No correlation between sST2 concentrations and platelet counts was found in the ITP patients with active disease. The plasma levels of IL-33 in the ITP patients with active disease were significantly decreased, and the plasma levels of sST2 were significantly increased compared with the normal controls. The ratio of sST2/IL-33 in the patients with active disease was significantly increased compared with the normal and remission groups (P b 0.01). However, there was no significant difference between the patients in remission and normal controls. 
CONCLUSION
This study concluded that, IL-33 may contribute to the pathogenesis of ITP. It could be a potential biomarker that diagnose and
